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Introduction
Changes in the structures of glycans on the surfaces of eukaryotic cells can be important biomarkers for developmental or disease states. Improved methods are needed
for the detection and analysis of alterations in glycan structures. Carbohydrate binding proteins such as lectins have potential for the recognition of changes in glycan
structure.
Host-pathogen interactions frequently involve the recognition of host carbohydrates by proteins of bacteria or viruses. Many bacterial toxins have evolved to interact with
host cell receptors or with a specific tissue due to lectin like properties. The toxins from Bacillus thuringiensis have been shown to have carbohydrate binding abilities, in
particular N-Acetylgalactosamine (GalNAc) has been shown to inhibit the binding of the toxin Cry1Ac. GalNAc has been shown to be an important marker in many
diseases such as breast cancer and colon carcinogenesis. Moreover, changes in GalNAc glycosylation have been identified in many disorders such as cystic fibrosis,
neuromuscular disorders and nephropathy. Here we describe the purification of a GalNAc binding protein of bacterial origin that may have potential in the development of
diagnostic assays.
2. Cloning of truncated cry1Ac gene
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3. The Expression of tCry1Ac in E. coli
5. ELLA of tCry1Ac and commercial lectins
Figure.1. Cloning of a truncated cry1Ac (tcry1Ac)
gene into an expression vector. The binding region
is marked on the gene and is on the domain III of
the protein. This vector was used for both the
tCry1aAc and the binding domain (CryD3).
Figure.2. Expression of tCry1Ac in E.
coli.
1, 6; Broad range protein ladder, 2; 2
hours post induction, 3; 3 hours post
induction, 4; 4 hours post induction, 5;
overnight post induction
4. Purification of tCry1Ac by IMAC 6. Affinity ELLA of tCry1Ac to GalNAc
Conclusions and future work
We have shown that truncated forms of the Bacillus thuringiensis toxin (Cry1Ac) have been cloned, expressed, purified and their binding activity assessed on ELLA’s.
Significantly the recombinant tCry1Ac has a higher specificity for GalNAc than commercial lectins while the binding domain CryD3 retains the specificity for GalNAc also.
This is very significant as the binding domain of Cry1Ac is 16kDa, which may be easier to manipulate than the larger tCry1Ac (69kDa). ELLA’s will be carried out on the
recombinant tCry1Ac and CryD3 to examine the stability of the proteins. Further studies will be carried out on the affinity and specificity of tCry1Ac and CryD3 by
mutagenesis. It is planned to use these carbohydrate binding proteins in the analysis and detection of O-glycosylation in host-pathogen interactions and pathogenesis.
These proteins could also be immobilised onto novel bio-affinity surfaces which would prove extremely useful in the detection, analysis and separation of glycans and
glycoproteins.
Figure.4. ELLA showing binding of tCry1Ac, CryD3 and
commercial lectins to GalNAc - BSA. The specificity of
each commercial lectin is highlighted. All lectins and
tCry1Ac and CryD3 are at a concentration of 10µg/mL.
tCry1Ac clearly shows very strong binding to GalNac .
Figure.5. ELLA showing the linear response of
recombinant tCry1Ac to the GalNAc-BSA. Inhibition
assays showed that the interaction is GalNAc
specific.
Figure.3. Purification of tCry1Ac by IMAC
1; Protein marker (broad range), 2; Flow
through, 3; 20mM imidazole wash, 4,5,6;
40mM imidazole wash, 7,8,9,10; Elution
300mM imidazole
1. Results
Two truncated forms of Cry1Ac
have been cloned, expressed in
Escherichia coli and purified by
Immobilised Metal Affinity
Chromatography (IMAC) (Figs 1-3).
The binding abilities of both
proteins have been analysed in an
Enzyme Linked Lectin Assay
(ELLA). Fig 4 shows a comparison
of the performances of the rCry1Ac
proteins in comparison to
commercial lectins as measured by
ELLA. tCry1Ac clearly shows
stronger binding to GalNAc than
the commercial lectins. Inhibition
assays showed that the
interactions are GalNAc specific.
